cis-4-methylperhydroquinoxaline | 5467-39-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: cis-4-methylperhydroquinoxaline
• 英文别名: (4Ar,8as)-1-methyldecahydroquinoxaline；(4aS,8aR)-4-methyl-2,3,4a,5,6,7,8,8a-octahydro-1H-quinoxaline
• CAS: 5467-39-0
• 化学式: C₉H₁₈N₂
• 分子量: 154.255
• InChiKey: YKNDCKWOYKGTBO-BDAKNGLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cis-4-methylperhydroquinoxaline 、 5,11-二氢-11-氯乙酰基-6H-吡啶并[2.3-b][1,4]苯并二氮卓-6-酮 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 以16%的产率得到11-[2-(cis-4-methylperhydro-1-quinoxalinyl)acetyl]-6,11-dihydro-5H-benzo[e]pyrido[3,2-b][1,4]diazepin-6-one
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of pirenzepine analogs bearing a 1,2-cyclohexanediamine and perhydroquinoxaline units in exchange for the piperazine ring as antimuscarinics

  摘要：

  Pirenzepine (2) is one of the most selective muscarinic M-1 versus M-2 receptor antagonists known. A series of 2 analogs, in which the piperazyl moiety was replaced by a cis-and trans-cyclohexane-1,2-diamine (3-6) or a trans-and cis-perhydroquinoxaline rings (7 and 8) were prepared, with the aim to investigate the role of the piperazine ring of 2 in the interaction with the muscarinic receptors. The structural change leading to compounds 3-6 abolished in binding assays the muscarinic M-1/M-2 selectivity of 2, due to an increased M-2 affinity. Rather, compounds 3-6 displayed a reversed selectivity showing more affinity at the muscarinic M-2 receptor than at all the other subtypes tested. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.06.025
• 作为产物：
  描述：

  benzyl cis-4-methylperhydro-1-quinoxalinecarboxylate 在 氢溴酸 、 溶剂黄146 作用下， 反应 2.0h， 以71%的产率得到cis-4-methylperhydroquinoxaline
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of pirenzepine analogs bearing a 1,2-cyclohexanediamine and perhydroquinoxaline units in exchange for the piperazine ring as antimuscarinics

  摘要：

  Pirenzepine (2) is one of the most selective muscarinic M-1 versus M-2 receptor antagonists known. A series of 2 analogs, in which the piperazyl moiety was replaced by a cis-and trans-cyclohexane-1,2-diamine (3-6) or a trans-and cis-perhydroquinoxaline rings (7 and 8) were prepared, with the aim to investigate the role of the piperazine ring of 2 in the interaction with the muscarinic receptors. The structural change leading to compounds 3-6 abolished in binding assays the muscarinic M-1/M-2 selectivity of 2, due to an increased M-2 affinity. Rather, compounds 3-6 displayed a reversed selectivity showing more affinity at the muscarinic M-2 receptor than at all the other subtypes tested. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.06.025

文献信息

• [EN] PEPTIDE DEFORMYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PEPTIDE DÉFORMYLASE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009061879A1

  公开（公告）日：2009-05-14

  The present invention is directed to certain 2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I), wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

  本发明涉及某些2-(烷基)-3-[2-(5-氟-4-嘧啶基)肼基]-3-氧代丙基}羟甲酰胺衍生物，含有它们的组合物，以及这些化合物在抑制细菌肽变形酶（PDF）活性和治疗细菌感染中的用途。具体而言，该发明涉及式（I）的化合物，其中R1、R2和R3在此有定义，并且其药用盐。本发明的这些化合物是细菌肽变形酶抑制剂，可用于治疗细菌感染。
• PEPTIDE DEFORMYLASE INHIBITORS
  申请人：Qin Donghui

  公开号：US20090306066A1

  公开（公告）日：2009-12-10

  The present invention is directed to certain 2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I): wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

  本发明涉及某些2-(烷基)-3-[2-(5-氟-4-嘧啶基)肼基]-3-氧代丙基}羟基甲酰胺衍生物，包含它们的组合物，这些化合物在抑制细菌肽变形酶（PDF）活性和治疗细菌感染方面的使用。具体而言，本发明涉及式（I）的化合物：其中R1，R2和R3在此定义，并且其药学上可接受的盐。本发明的化合物是细菌肽变形酶抑制剂，可用于治疗细菌感染。
• Peptide deformylase inhibitors
  申请人：GlaxoSmithKline LLC

  公开号：US07893056B2

  公开（公告）日：2011-02-22

  The present invention is directed to certain 2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I): wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

  本发明涉及某些2-(烷基)-3-[2-(5-氟-4-嘧啶基)肼基]-3-氧代丙基}羟基甲酰胺衍生物，含有它们的组合物，以及在抑制细菌肽变形酶（PDF）活性和治疗细菌感染方面使用这种化合物。具体而言，本发明涉及式（I）的化合物：其中R1、R2和R3在此定义，并且其药学上可接受的盐。本发明的化合物是细菌肽变形酶抑制剂，可用于治疗细菌感染。
• US7893056B2
  申请人：——

  公开号：US7893056B2

  公开（公告）日：2011-02-22
• [EN] BICYCLIC NITROGEN-CONTAINING SATURATED HETEROCYCLIC DERIVATIVES<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES SATURÉS À TENEUR EN AZOTE, BICYCLIQUES
  申请人：DAIICHI SANKYO CO LTD

  公开号：WO2011068171A1

  公开（公告）日：2011-06-09

  　慢性関節リウマチ、多発性硬化症、クローン病や潰瘍性大腸炎などの炎症性腸疾患、乾癬などを代表とする自己免疫性疾患や、移植臓器の拒絶反応、アレルギー疾患などの予防又は治療効果を有する化合物、それら化合物を含有する医薬組成物、又は医薬組成物の有効量を哺乳動物に投与することを特徴とする、自己免疫疾患の予防方法又は治療方法を提供すること。 一般式（Ｉ）を有する化合物又はその薬理上許容される塩である。